Proprietary formulation technology being applied to potentially enhance properties of nimacimab
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience,
Skye Bioscience (SKYE) partners with Arecor Therapeutics to develop an enhanced formulation of obesity drug nimacimab using Arestatâ„¢ technology. Nimac
Revenue: Increased by 11% to GBP 5.1 million.R&D Expenses: Decreased by GBP 2.4 million to GBP 3 million.SG&A Expenses: Remained flat at GBP 6.2 million.Cash P
THAMES VENTURES VCT 2 PLCLEI: 21380035MV1VRYEXPR95 07 AUGUST 2024CORRECTION - FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 The Board notes that the...
The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
----------
Sound Energy PLC - Moroccan-focused...
Arecor Therapeutics PLC on Monday said it now expects to require new funding in the third quarter of this year.
Shares in the Essex, England-based biopharmaceutical firm shares fell 26% in response...
Arecor Therapeutics PLC on Monday celebrated results of its insulin AT278.
The Essex, England-based biopharmaceutical firm said AT278 showed a significantly accelerated pharmacokinetic and...
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
----------
Arecor Therapeutics PLC - West Sussex, England-based...